# Chemotherapy for Patients With Osteosarcoma

> **NCT00523419** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 32 (actual)

## Conditions studied

- Osteosarcoma

## Interventions

- **DRUG:** Pemetrexed

## Key facts

- **NCT ID:** NCT00523419
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-09
- **Primary completion:** 2009-06
- **Final completion:** 2010-06
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2011-06-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00523419

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00523419, "Chemotherapy for Patients With Osteosarcoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00523419. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*